EBS

#3040
Emergent BioSolutions Inc. Common Stock
8.3 0 USD
-0.12%
Sektor: Gesundheitswesen
Basis: USD
Gewinnwährung: USD
Tagesspanne
8.26
8.32
Jahresspanne
7.56
11.46
Tagesänderung
-0.12%
Monatliche Änderung
-0.48%
6 month change
-22.57%
Jahresänderung
-22.57%
Vorheriger Schlusskurs
8.3 1
Open
8.2 7
Tief
8.2 6
High
8.3 2
Volumen
583
Vollständige Grafik anzeigen

Financials

Übersicht Finanzbericht Statistik
Vierteljährlich Jährlich
  • Market Capitalization 428.25 M
  • Employee 900
  • Founded 1998
  • CEO Robert G. Kramer Sr. | Joseph C. Papa
  • Website www.emergentbiosolutions.com
  • Headquarter Delaware, United States
  • FIGI BBG000GW06J7
  • Industry Arzneimittelhersteller – spezialisierte und Generika
Gesamtumsatz
Jahresüberschuss
Unverwässertes Ergebnis je Aktie (Unverwässertes EPS)
Gesamtverschuldung
Freier Cashflow
Zahlungsmittel und Zahlungsmitteläquivalente
Kurs-Gewinn-Verhältnis
13.29
Preis-Umsatz-Verhältnis
0.94

Emergent BioSolutions Inc. Common Stock

Emergent BioSolutions Inc. is an American multinational specialty biopharmaceutical company headquartered in Gaithersburg, Maryland. It develops vaccines and antibody therapeutics for infectious diseases and opioid overdoses, and it provides medical devices for biodefense purposes. Among the company's products are the controversial BioThrax, the only anthrax vaccine licensed by the U.S. Food and Drug Administration and Narcan for the emergency treatment of opioid overdose. The company also manufactures pharmaceuticals for infectious diseases like cholera and typhoid. During the COVID-19 pandemic, Emergent BioSolutions also produced Johnson & Johnson/Janssen and Oxford–AstraZeneca vaccines at one of its plants; however, this was marked by contamination and other production issues, and millions of doses of vaccine had to be discarded.

Nachrichten